Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial Academic Article Article uri icon

Overview

MeSH Major

  • Chickenpox Vaccine
  • HIV Infections
  • Measles-Mumps-Rubella Vaccine
  • Mumps
  • Rubella
  • Vaccination

abstract

  • In treatment-experienced patients with NNRTI resistance, treatment with TMC125 achieved better virological suppression at week 24 than did placebo. The safety and tolerability profile of TMC125 was generally comparable with placebo.

publication date

  • July 7, 2007

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(07)61047-2

PubMed ID

  • 17617270

Additional Document Info

start page

  • 29

end page

  • 38

volume

  • 370

number

  • 9581